Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | DBH | P09172 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA7 | P43166 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | SNCA | P37840 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9084566 | 0.86 | APP (0.45) | KDM4EGAAPOLBTYRDAO | |
| SCHEMBL9083426 | 0.82 | KDM4E (0.41) | KDM4ECA12CA1CA2CA9 | |
| SCHEMBL9083710 | 0.76 | APP (0.42) | KDM4EGAACA12CA1CA2 | |
| SCHEMBL8993667 | 0.73 | APP (0.48) | KDM4EGAAHDAC6CA12CA1 | |
| SCHEMBL108994 | 0.72 | KDM4E (0.58) | KDM4EGAADBHRECQLHDAC6 | |
| SCHEMBL28459149 | 0.69 | CES2 (0.63) | KDM4EGAADBHRECQLHDAC6 | |
| SCHEMBL27833057 | 0.68 | KDM4E (0.62) | KDM4EGAADBHRECQLHDAC6 | |
| SCHEMBL2988488 | 0.68 | KDM4E (0.74) | KDM4EGAADBHRECQLHDAC6 | |
| SCHEMBL361231 | 0.67 | POLB (0.61) | GAACA12CA1CA2CA7 | |
| SCHEMBL2116163 | 0.65 | DAO (0.50) | KDM4ETYRDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379177-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPIGMENTATION | Revance Therapeutics, Inc. (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010078244-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPIGMENTATION | REVANCE THERAPEUTICS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100166689-A1 | Compositions and Methods for Treating Hyperpigmentation | REVANCE THERAPEUTICS, INC. (US) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100166689-A1 | Compositions and Methods for Treating Hyperpigmentation | TYR, CUTA, SLC25A21 | KDM4E 1221/4885GAA 677/4885DBH 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.